PCM Encore LLC Buys Shares of 7,399 Gilead Sciences, Inc. $GILD

Key Points

• PCM Encore LLC acquired 7,399 Gilead Sciences shares worth approximately $935,000 in the second quarter. Other institutions also initiated positions, and institutional investors collectively own 83.67% of Gilead’s stock.
• Analysts maintain a generally positive outlook, with 24 Buy ratings and five Holds producing a “Moderate Buy” consensus and an average price target of $158.04.
• Gilead reported quarterly revenue of $7.80 billion, exceeding expectations, and declared a quarterly dividend of $0.82 per share, equivalent to a 2.3% annual yield.

PCM Encore LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm bought 7,399 shares of the biopharmaceutical company's stock, valued at approximately $935,000.

Other institutional investors have also modified their holdings of the company. Trillium Asset Management LLC acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at about $9,490,000. Altman Advisors Inc. purchased a new stake in shares of Gilead Sciences in the second quarter valued at about $2,771,000. Vise Technologies Inc. acquired a new stake in Gilead Sciences during the second quarter worth about $15,173,000. OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in Gilead Sciences during the second quarter worth about $1,801,000. Finally, E Fund Management Co. Ltd. purchased a new position in Gilead Sciences during the second quarter worth about $6,802,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

GILD has been the topic of several recent analyst reports. Barclays decreased their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 29th. HSBC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Truist Financial decreased their price objective on Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a report on Tuesday, July 7th. Daiwa Securities Group lowered their price objective on Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating for the company in a research report on Tuesday, May 19th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Twenty-four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $158.04.

Gilead Sciences Trading Down 2.8%

NASDAQ GILD opened at $143.44 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock has a market capitalization of $177.86 billion, a P/E ratio of -53.72 and a beta of 0.32. The firm's 50-day moving average is $131.56 and its two-hundred day moving average is $136.52. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business's revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the business earned $2.01 earnings per share. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.51 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. Gilead Sciences's dividend payout ratio (DPR) is presently -122.85%.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead’s collaboration with Nucleai highlights a potential strategic shift toward data-driven oncology. Nucleai’s spatial-biology and artificial-intelligence capabilities could help Gilead identify biomarkers, improve patient selection and support its cancer-drug pipeline, although the financial impact remains uncertain. Does Gilead Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?
• Positive Sentiment: BMO Capital reaffirmed its Buy rating, reinforcing the view that Gilead’s HIV franchise, oncology investments and pipeline can support further gains. BMO Capital Reaffirms Buy Rating on Gilead Sciences
• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast from a loss of $1.05 to a loss of $0.65 and increased its FY2027 estimate from $9.11 to $9.30. Several quarterly estimates for late 2026 and 2027 were also raised, suggesting improving expectations for future profitability.
• Neutral Sentiment: The recent rally extended to seven consecutive sessions, indicating strong momentum, but the subsequent consolidation may reflect profit-taking as the stock trades near its 52-week high. Gilead Rises for the Seventh Straight Session
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82, equivalent to $3.28 annually and a yield of roughly 2.3%. The payout supports income-oriented investors, though the reported negative payout ratio reflects currently distorted earnings.
• Negative Sentiment: Zacks lowered its FY2028 EPS forecast from $10.00 to $9.58 and cut estimates for Q1 and Q2 2028. Although several nearer-term estimates increased, the mixed revisions signal uncertainty around the longer-term earnings trajectory.
• Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares for approximately $415,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan and left him with substantial holdings, making it a limited bearish signal, but insider selling can weigh modestly on sentiment. Gilead Sciences CFO Sells 3,000 Shares

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider directly owned 118,234 shares in the company, valued at $16,273,727.76. This trade represents a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the completion of the sale, the chief financial officer directly owned 165,646 shares of the company's stock, valued at $22,918,780.56. The trade was a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 82,000 shares of company stock worth $10,837,860. Insiders own 0.30% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source